Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The session is scheduled for September 16 at 8:30 a.m. EDT and will be webcast live, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website.
The Morgan Stanley Global Healthcare Conference is a prominent event that brings together industry leaders, investors, and analysts to discuss the latest trends and innovations in healthcare. Helus Pharma's participation underscores the company's commitment to engaging with the investment community and highlighting its progress in developing treatments for depression, anxiety, and other mental health conditions. For investors, the fireside chat offers a valuable opportunity to gain insights into the company's strategic direction, clinical milestones, and potential catalysts.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is dedicated to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape by providing durable improvements in mental health.
The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, also a proprietary NSA, is in Phase 2 for generalized anxiety disorder. These programs target conditions that affect millions worldwide and represent significant market opportunities. The Breakthrough Therapy Designation for HLP003 highlights the potential of the company's approach and may expedite its development and review process.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For company updates and to learn more, visit www.helus.com. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP. To view the full press release, visit https://ibn.fm/r0jfC.
The announcement comes as the biotechnology and pharmaceutical sectors continue to attract significant investor interest, particularly in the area of mental health therapeutics. With a growing global burden of mental illness and limited treatment options, companies like Helus Pharma that are developing innovative therapies could play a crucial role in addressing this unmet need. The fireside chat at the Morgan Stanley conference may serve as a platform for Helus Pharma to communicate its vision and milestones to a broad audience of potential investors and partners, potentially influencing the company's stock performance and future financing opportunities.
BioMedWire (BMW), a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, disseminated the announcement. BMW is one of over 75 brands within the Dynamic Brand Portfolio@IBN, providing access to a vast network of wire solutions, article syndication to more than 5,000 outlets, enhanced press release optimization, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com.
